JP2007534698A5 - - Google Patents

Download PDF

Info

Publication number
JP2007534698A5
JP2007534698A5 JP2007509735A JP2007509735A JP2007534698A5 JP 2007534698 A5 JP2007534698 A5 JP 2007534698A5 JP 2007509735 A JP2007509735 A JP 2007509735A JP 2007509735 A JP2007509735 A JP 2007509735A JP 2007534698 A5 JP2007534698 A5 JP 2007534698A5
Authority
JP
Japan
Prior art keywords
peptide
purified
complex
acid ester
gallic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007509735A
Other languages
English (en)
Japanese (ja)
Other versions
JP5036533B2 (ja
JP2007534698A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/014254 external-priority patent/WO2005105057A1/en
Publication of JP2007534698A publication Critical patent/JP2007534698A/ja
Publication of JP2007534698A5 publication Critical patent/JP2007534698A5/ja
Application granted granted Critical
Publication of JP5036533B2 publication Critical patent/JP5036533B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007509735A 2004-04-23 2005-04-25 持続放出製剤 Expired - Fee Related JP5036533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56524704P 2004-04-23 2004-04-23
US60/565,247 2004-04-23
PCT/US2005/014254 WO2005105057A1 (en) 2004-04-23 2005-04-25 Sustained release formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011196883A Division JP5829870B2 (ja) 2004-04-23 2011-09-09 持続放出製剤
JP2011196884A Division JP2012036194A (ja) 2004-04-23 2011-09-09 持続放出製剤

Publications (3)

Publication Number Publication Date
JP2007534698A JP2007534698A (ja) 2007-11-29
JP2007534698A5 true JP2007534698A5 (enExample) 2008-02-28
JP5036533B2 JP5036533B2 (ja) 2012-09-26

Family

ID=34967842

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007509735A Expired - Fee Related JP5036533B2 (ja) 2004-04-23 2005-04-25 持続放出製剤
JP2011196883A Expired - Fee Related JP5829870B2 (ja) 2004-04-23 2011-09-09 持続放出製剤
JP2011196884A Pending JP2012036194A (ja) 2004-04-23 2011-09-09 持続放出製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011196883A Expired - Fee Related JP5829870B2 (ja) 2004-04-23 2011-09-09 持続放出製剤
JP2011196884A Pending JP2012036194A (ja) 2004-04-23 2011-09-09 持続放出製剤

Country Status (15)

Country Link
US (2) US7323169B2 (enExample)
EP (1) EP1750683B1 (enExample)
JP (3) JP5036533B2 (enExample)
KR (1) KR101201638B1 (enExample)
CN (2) CN1997356A (enExample)
AU (1) AU2005237542B2 (enExample)
CA (1) CA2563185C (enExample)
DK (1) DK1750683T3 (enExample)
ES (1) ES2400687T3 (enExample)
IL (1) IL178596A (enExample)
PL (1) PL1750683T3 (enExample)
PT (1) PT1750683E (enExample)
SI (1) SI1750683T1 (enExample)
WO (1) WO2005105057A1 (enExample)
ZA (1) ZA200609401B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997356A (zh) * 2004-04-23 2007-07-11 安姆根有限公司 持续释放制剂
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7252834B2 (en) 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
NZ565535A (en) * 2005-06-30 2011-03-31 Ipsen Pharma Sas GLP-1 pharmaceutical compositions
CA2642632A1 (en) * 2006-02-15 2007-10-18 Gammacan Ltd. Immunoglobulins from vitiligo plasma for melanoma therapy
MX2009000685A (es) * 2006-07-21 2009-01-30 Amgen Inc Metodo para detectar y/o cuantificar hepcidina en una muestra.
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP2257274A4 (en) * 2008-02-21 2011-07-20 Vatrix Medical Inc TREATMENT OF ANEURYSMA USING A BIND WEAVE STABILIZING AGENT COMBINED WITH A DISPENSER
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8444624B2 (en) 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
JP2014516695A (ja) 2011-05-18 2014-07-17 バトリックス・メディカル・インコーポレイテッド 血管安定化用被覆バルーン
BR112014015003A2 (pt) * 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
EP3155002B1 (en) 2014-06-10 2019-11-27 Amgen Inc. Apelin polypeptides
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
EP3634507B1 (en) * 2017-06-07 2025-01-15 EGY-Nano Pharma, LP Oral prolonged drug delivery platforms
WO2020027881A1 (en) 2018-08-03 2020-02-06 Nectero Medical, Inc. Purified pentagalloyl glucose and devices for delivery
WO2020227437A1 (en) * 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
CN119326891B (zh) * 2024-10-31 2025-07-01 中国人民解放军空军军医大学 Ei24激动剂以及在制备抑制食管鳞癌增殖的制剂的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
GB929405A (en) 1958-12-22 1963-06-19 Upjohn Co Processes for the encapsulation of particles
CH498653A (fr) 1968-03-29 1970-11-15 Kobayashi Takehiko Procédé d'encapsulation de matières hydrophobes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP2744572B2 (ja) * 1993-02-17 1998-04-28 鐘紡株式会社 ポリフェノール化合物含有皮膚外用剤組成物の変色防止方法
JPH06345668A (ja) * 1993-06-07 1994-12-20 Shibayagi:Kk 感染防御組成物およびその用途
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
WO1998010649A1 (en) 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6531154B1 (en) * 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
EP1003483A1 (en) * 1997-07-23 2000-05-31 Perio Products Ltd Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
AU766959B2 (en) * 1998-04-20 2003-10-30 Genzyme Corporation Drug delivery of proteins from polymeric blends
JP2000080027A (ja) * 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd 徐放性製剤
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
CA2389304A1 (en) 1999-11-01 2001-05-10 Corinne S. Lengsfeld Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
US6759064B2 (en) * 2001-02-22 2004-07-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
JP5013152B2 (ja) * 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
US20040142048A1 (en) * 2002-02-22 2004-07-22 Morre Dorothy M. Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer
US20050271603A1 (en) * 2002-07-26 2005-12-08 Stephanie Krammer Compositions comprising lactoferrin
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
CN1997356A (zh) * 2004-04-23 2007-07-11 安姆根有限公司 持续释放制剂

Similar Documents

Publication Publication Date Title
CA2563185A1 (en) Sustained release formulations of a peptide or protein and a purified gallic acid ester
ES2529300T3 (es) Proteínas de fusión de albúmina
JP2022518695A5 (enExample)
TWI250165B (en) Hepatitis C inhibitor tri-peptides
JP2022513223A5 (enExample)
JP5909182B2 (ja) 代謝性症候群を予防し又は治療するための方法
TWI482626B (zh) 胃腸道病症的治療
JP2011173914A5 (enExample)
JP2011530599A5 (enExample)
JP2010513506A5 (enExample)
JP2022514255A5 (enExample)
JP2013532644A5 (enExample)
TW200521144A (en) Macrocyclic peptides active against the hepatitis c virus
CA2452923A1 (en) Peptide-based compounds for targeting integrin receptors
JP2010518079A5 (enExample)
JP2013504589A5 (enExample)
CN102307896A (zh) 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
ME02335B (me) Activin-actrii antagonisti i upotreba za liječenje anemije
JP2008500373A5 (enExample)
US6699973B1 (en) Antibodies to peptides that target GIT receptors and related methods
AR025307A1 (es) Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
CN110114065A (zh) 通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生
JP2024506940A5 (enExample)
JP2012504619A5 (enExample)
JP2020203954A (ja) 結腸洗浄及び胃腸障害の治療のための組成物